A Phase II Study of Combined Fulvestrant (Faslodex) and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure

Trial Profile

A Phase II Study of Combined Fulvestrant (Faslodex) and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2016

At a glance

  • Drugs Everolimus (Primary) ; Fulvestrant (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Dec 2015 Results assessing genomic evolution on endocrine therapy and mTOR inhibition presented at the 38th Annual San Antonio Breast Cancer Symposium.
    • 02 Jun 2015 Results assessing genomic alterations presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 21 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top